Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1005944 | 1.00 | ALDH1A1 (0.42) | ALDH1A1PKMLMNATSHRPARP1 | |
| SCHEMBL20980365 | 1.00 | ALDH1A1 (0.42) | ALDH1A1PKMLMNATSHRPARP1 | |
| SCHEMBL20959501 | 1.00 | ALDH1A1 (0.42) | ALDH1A1PKMLMNATSHRPARP1 | |
| SCHEMBL7522167 | 0.87 | ALDH1A1 (0.37) | ALDH1A1PKMLMNATSHRPARP1 | |
| O-Xylene SCHEMBL11227111 | 0.85 | TSHR (0.39) | LMNATSHRPARP1 | |
| SCHEMBL6155008 | 0.79 | OR51E2 (0.37) | ALDH1A1PKM | |
| SCHEMBL9795016 | 0.77 | ALDH1A1 (0.39) | ALDH1A1PKMLMNATSHRPARP1 | |
| SCHEMBL23177090 | 0.74 | — | — | |
| SCHEMBL2904793 | 0.73 | ALDH1A1 (0.55) | ALDH1A1PKMLMNATSHRPARP1 | |
| SCHEMBL1189771 | 0.73 | ALDH1A1 (0.55) | ALDH1A1PKMLMNATSHRPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744127-B2 | MDR-reversing 8-hydroxy-quinoline derivatives | MAGYAR TUDOMÁNYOS AKADÉMIA TERMÉSZETTUDOMÁNYI KUTATÓKÖZPONT (HU) | 2020-08-18 | — | — | US | claimed |
| US-5013836-A | Process for methylating a hindered nitrogen atom in a polysubstituted diazacycloalkan-2-one | THE B. F. GOODRICH COMPANY (US) | 1991-05-07 | — | — | US | claimed |
| US-4455401-A | 2-Keto-diazacycloalkane-urethane oligomers and U-V light stabilized compositions | THE B. F. GOODRICH COMPANY (US) | 1984-06-19 | — | — | US | claimed |
| EP-0095066-A2 | 2-Keto-diazacycloalkane-urethane oligomers and UV light stabilized compositions | The B.F. GOODRICH Company (US) | 1983-11-30 | — | — | EP | claimed |
| WO-2024239187-A1 | USE OF BMPR1B INHIBITOR IN INDUCED DEVELOPMENT, AND INDUCTION CULTURE MEDIUM | 睿健医药科技(苏州)有限公司 | 2024-11-28 | — | — | WO | disclosed |
| CN-118995607-A | Application of BMPR1B inhibitor in induced development and induced culture medium | 睿健医药科技(苏州)有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118994114-A | Pyrazolyl piperazinone compounds, pharmaceutical compositions and application thereof | 睿健医药科技(苏州)有限公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-3440070-B1 | MDR-REVERSING 8-HYDROXY-QUINOLINE DERIVATIVES | MTA TERMESZETTUDOMANYI KUTATOKOEZPONT (HU) | 2024-10-30 | — | — | EP | disclosed |
| US-10744127-B2 | MDR-reversing 8-hydroxy-quinoline derivatives | MAGYAR TUDOMÁNYOS AKADÉMIA TERMÉSZETTUDOMÁNYI KUTATÓKÖZPONT (HU) | 2020-08-18 | — | — | US | disclosed |
| US-20190151306-A1 | MDR-REVERSING 8-HYDROXY-QUINOLINE DERIVATIVES | MAGYAR TUDOMÁNYOS AKADÉMIA TERMÉSZETTUDOMÁNYI KUTATÓKÖZPONT (HU) | 2019-05-23 | — | — | US | disclosed |
| US-20140275017-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275017-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-09-18 | — | — | US | disclosed |
| US-4297497-A | Synthesis of 2-keto-1,4-diazacycloalkanes | THE B. F. GOODRICH COMPANY | 1981-10-27 | — | — | US | disclosed |
| US-4292240-A | PHOTOSTABILIZERS FOR PLASTICS | THE B. F. GOODRICH COMPANY (US) | 1981-09-29 | — | — | US | disclosed |
| EP-0029088-A2 | Synthesis of 2-keto-1,4-diazacycloalkanes | The B.F. GOODRICH Company (US) | 1981-05-27 | — | — | EP | disclosed |
| EP-0024337-A1 | Synthesis of 2-keto-1,4-diazacycloalkanes | The B.F. GOODRICH Company (US) | 1981-03-04 | — | — | EP | disclosed |
| US-4190571-A | POLYOLEFINS | THE B. F. GOODRICH COMPANY (US) | 1980-02-26 | — | — | US | disclosed |
| US-4167512-A | Synthesis of 2-keto-1,4-diazacycloalkanes | THE B. F. GOODRICH COMPANY (US) | 1979-09-11 | — | — | US | disclosed |
| EP-0001559-A2 | Synthesis of 2-keto-1,4-diazacycloalkanes | The B.F. GOODRICH Company (US) | 1979-05-02 | — | — | EP | disclosed |
| EP-0001284-A1 | UV-light stabilized compositions containing substituted 2-keto-1,4-diazacycloalkanes | The B.F. GOODRICH Company (US) | 1979-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151306-A1 | MDR-REVERSING 8-HYDROXY-QUINOLINE DERIVATIVES | ABCC1, ABCB1, ABCC8 | ALDH1A1 949/4885PKM 2739/4885LMNA 2388/4885 |
| US-10744127-B2 | MDR-reversing 8-hydroxy-quinoline derivatives | ABCC1, ABCB1, ABCC8 | ALDH1A1 949/4885PKM 2739/4885LMNA 2388/4885 |
| US-20140275017-A1 | CGRP RECEPTOR ANTAGONISTS | BDKRB1, CALCRL, BDKRB2 | ALDH1A1 1818/4885PKM 2679/4885LMNA 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.